secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000950170-22-007824
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q1 rev $24.5M, net loss $44.6M; latozinemab shows 54% disease progression delay in FTD-C9orf72
--------------------------------------------------------------------------------

- Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.
- Cash, cash equivalents, and marketable securities $868.6M; sufficient to fund operations into mid-2024.
- INFRONT-2 Phase 2: latozinemab in FTD-C9orf72 showed ~54% annual delay in disease progression vs matched control.
- AL101 Phase 1 enrollment completed; data expected H2 2022. AL044 Phase 1 to initiate H2 2022.
- Gary Romano, M.D., Ph.D., joins as CMO on May 23, 2022; Marc Grasso, M.D., joined as CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/0000950170-22-007824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/alec-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer